BOK Financial Private Wealth Inc. Buys 395 Shares of Edwards Lifesciences Co. (NYSE:EW)

BOK Financial Private Wealth Inc. increased its holdings in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 0.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,316 shares of the medical research company’s stock after purchasing an additional 395 shares during the quarter. BOK Financial Private Wealth Inc.’s holdings in Edwards Lifesciences were worth $5,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Lindbrook Capital LLC increased its stake in Edwards Lifesciences by 14.6% during the 1st quarter. Lindbrook Capital LLC now owns 738 shares of the medical research company’s stock worth $87,000 after buying an additional 94 shares during the period. Hoylecohen LLC boosted its holdings in shares of Edwards Lifesciences by 1.0% in the 1st quarter. Hoylecohen LLC now owns 9,923 shares of the medical research company’s stock valued at $1,168,000 after buying an additional 100 shares in the last quarter. Midwest Professional Planners LTD. raised its position in Edwards Lifesciences by 0.5% in the 4th quarter. Midwest Professional Planners LTD. now owns 21,563 shares of the medical research company’s stock valued at $2,793,000 after purchasing an additional 105 shares during the last quarter. McIlrath & Eck LLC raised its position in Edwards Lifesciences by 7.2% in the 4th quarter. McIlrath & Eck LLC now owns 1,584 shares of the medical research company’s stock valued at $205,000 after purchasing an additional 106 shares during the last quarter. Finally, Pinnacle Bancorp Inc. raised its position in Edwards Lifesciences by 18.6% during the 1st quarter. Pinnacle Bancorp Inc. now owns 701 shares of the medical research company’s stock worth $83,000 after buying an additional 110 shares during the last quarter. 82.54% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 2.2 %

Shares of Edwards Lifesciences stock traded down $2.29 on Tuesday, hitting $103.17. The company had a trading volume of 37,517 shares, compared to its average volume of 2,501,607. The stock has a market capitalization of $63.96 billion, a price-to-earnings ratio of 45.65, a P/E/G ratio of 3.13 and a beta of 1.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.60 and a current ratio of 3.37. The stock has a 50 day moving average of $97.44 and a 200-day moving average of $105.15. Edwards Lifesciences Co. has a 1 year low of $85.58 and a 1 year high of $131.73.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences’s revenue was down .2% on a year-over-year basis. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.51 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $86.96, for a total value of $1,728,330.00. Following the sale, the chief executive officer now directly owns 157,353 shares of the company’s stock, valued at $13,683,416.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Daveen Chopra sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $98.31, for a total transaction of $98,310.00. Following the sale, the vice president now directly owns 19,911 shares in the company, valued at approximately $1,957,450.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the completion of the transaction, the chief executive officer now owns 157,353 shares in the company, valued at $13,683,416.88. The disclosure for this sale can be found here. Insiders have sold 81,062 shares of company stock worth $7,656,531 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EW. Morgan Stanley cut their price target on shares of Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating for the company in a report on Friday, July 15th. Canaccord Genuity Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Truist Financial decreased their target price on shares of Edwards Lifesciences from $140.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, July 20th. Canaccord Genuity Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $115.00 to $106.00 in a research note on Friday, July 29th. Finally, Cowen dropped their price objective on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $126.19.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

See Also

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.